These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31043741)

  • 21. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
    Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
    McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES
    Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
    Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
    Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
    Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
    Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
    Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
    Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
    Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
    Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.
    Saab R; Rodriguez-Galindo C; Matmati K; Rehg JE; Baumer SH; Khoury JD; Billups C; Neale G; Helton KJ; Skapek SX
    Cancer Res; 2009 Jan; 69(2):440-8. PubMed ID: 19147556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity.
    Clark W; Black EJ; MacLaren A; Kruse U; LaThangue N; Vogt PK; Gillespie DA
    Mol Cell Biol; 2000 Apr; 20(7):2529-42. PubMed ID: 10713176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
    Yang C; Li Z; Bhatt T; Dickler M; Giri D; Scaltriti M; Baselga J; Rosen N; Chandarlapaty S
    Oncogene; 2017 Apr; 36(16):2255-2264. PubMed ID: 27748766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt.
    Zhang J; Xu K; Liu P; Geng Y; Wang B; Gan W; Guo J; Wu F; Chin YR; Berrios C; Lien EC; Toker A; DeCaprio JA; Sicinski P; Wei W
    Mol Cell; 2016 Jun; 62(6):929-942. PubMed ID: 27237051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas.
    Ghazizadeh M; Jin E; Shimizu H; Fujiwara M; Arai S; Ohaki Y; Takemura T; Kawanami O
    Respiration; 2005; 72(1):68-73. PubMed ID: 15753637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
    Zhang YX; Sicinska E; Czaplinski JT; Remillard SP; Moss S; Wang Y; Brain C; Loo A; Snyder EL; Demetri GD; Kim S; Kung AL; Wagner AJ
    Mol Cancer Ther; 2014 Sep; 13(9):2184-93. PubMed ID: 25028469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cyclin D-CDK6 dimer helps to reshuffle cyclin-dependent kinase inhibitors (CKI) to overcome TGF-beta-mediated arrest and maintain CDK2 activity.
    Nataraj SE; Blain SW
    Cell Cycle; 2021 Apr; 20(8):808-818. PubMed ID: 33794722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Rb-CDK4/6 signaling pathway is critical in neural precursor cell cycle regulation.
    Ferguson KL; Callaghan SM; O'Hare MJ; Park DS; Slack RS
    J Biol Chem; 2000 Oct; 275(43):33593-600. PubMed ID: 10915795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
    Lukas C; Jensen SK; Bartkova J; Lukas J; Bartek J
    Hybridoma; 1999 Jun; 18(3):225-34. PubMed ID: 10475236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
    Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
    Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.